(Taiwan) CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology

January 16, 2025 12:00 PM AEDT | By Cision

(Taiwan) CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology — Image source: Kalkine Media

Recent News

Leadership Shake-Up: Scott Gregson to Lead ASIC as CEO

Southern Cross Gold Consolidated’s ASX Debut: Key Details for Investor...

Australian Banks Surge on ASX as Wall Street’s Banking Giants Deliver...

Youth Driving Change in Mining: How Young Australians Shape a Sustaina...

TAICHUNG, Jan. 16, 2025 /PRNewswire/ -- On November 2, 2024, China Medical University (CMU) and Healthcare System hosted the International Forum of Extracellular Vesicles Technology and Novel Therapeutics to highlight Taiwan's advancements and explore new horizons in biomedical applications. Professor Randy Schekman, the 2013 Nobel prize laureate in Physiology/Medicine, was invited as keynote speaker to share his insights in Extracellular Vesicles (EV) technology. Notable scholars and industrial leaders, such as Professor Andreas Möller, Professor Houjian Cai, Professor Le Thi Nguyet Minh, Professor Johannes Grillari, and members of the International Society for Extracellular Vesicles, the Asia Pacific Societies for Extracellular Vesicles, and the Taiwan Society for Extracellular Vesicles attended the forum to discuss the latest advancements in EV research, technology, and applications.

CEO Jeng (leftmost), President Hung (second from the left), Professor Schekman (second from the right) and Superintendent Cho (rightmost) attended the forum to discuss the potential of exosomal technology in clinical applications.

Dr. Chang-Hai Tsai, Chairman of CMU Healthcare System, stated that this forum marks a major breakthrough in exosomal technology in precision medicine and regenerative medicine. CMU Healthcare System aims to continue the endeavor of promoting the international presence of Taiwan-based biotech industries, and to deliver better personalized healthcare to the global community. EVs are known to play a key role in aging, inflammation, disease progression and inter-cellular communication. EVs or exosomes technology will become a landmark in biological preparation development and human health.

Professor Randy Schekman provided an in-depth view of the key bridging role of exosomes in inter-cellular communication, and the latest research on quantitative science-based methods for increasing the "cargo loading" efficiency of exosomes. In his keynote speech, Professor Schekman highlighted the potential of exosome technology in achieving therapeutic goals. The keynote was moderated by Dr. Mien-Chie Hung, President of CMU.

Dr. Long-Bin Jeng, CEO of CMU Development Committee, stated that CMU Healthcare System acquired notable results in exosome studies and development. Shine-On BioMedical Co. introduced the application of HLA-G targeted exosome in cancer treatment, and demonstrated innovative technology and current development progress: using targeted exosomes loaded with chemotherapy agent for effective inhibition of breast cancer cells while reducing side effects. Shine-On BioMedical is also working on Temodal, a chemotherapy agent indicated for brain cancer, to develop a nucleic acid pharmaceutical agent aimed at reducing resistance development. By carrying such agents through the blood brain barrier using HLA-G targeted exosomes, outstanding efficacy of difficult-to-treat brain tumors such as glioblastoma multiforme (GBM) can be achieved. This will provide significant benefits to cancer patients.

CMUH's Translational Medicine Research Center showcased dual-gene-engineered exosomes for improving neurological recovery after stroke. Partnering with Shine-Out BioTechnology Co., CMUH developed targeted exosome platforms for treating neurodegenerative diseases like Parkinson's and Alzheimer's. These platforms are designed to boost cellular repair and regeneration. Additionally, CMUH's Translational Cell Therapy Center advanced CD3ε nanobody-modified exosomes, which may generate dual-targeting CAR-T cells, highlighting the forum's commitment to clinical innovation.

Dr. Der-Yang Cho, Superintendent of CMUH, emphasized the potential of exosomal platforms in cancer and neurodegenerative treatments, aiming to reduce dosages and side effects. Despite challenges in scaling production, CMUH is dedicated to advancing clinical research and fostering international collaborations to bring cutting-edge medical technologies to patients.

CONTACT: Carolyn Chen, [email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Full Name

Mobile

By submitting your details above and clicking on the 'Download Report' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.

Markets

Disclaimer

Recent Articles

1

2

3

4

5

Investing Tips

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27